Buy Novo Nordisk. Here’s Why


🚨 🇩🇰 JPMorgan has turned bullish on Novo Nordisk’s new weight loss drug CagriSema which combines semaglutide with cagrilintide, and could help patients lose 25% of their body weight


Read Report: bit.ly/Novo-JPMBullish

Leave a comment